...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer Biology >The application of Clathrin Heavy Chain and Leukemia Inhibitory Factor Receptor in the differential diagnosis of benign and malignant hepatic lesions
【24h】

The application of Clathrin Heavy Chain and Leukemia Inhibitory Factor Receptor in the differential diagnosis of benign and malignant hepatic lesions

机译：网格蛋白重链和白血病抑制因子受体在肝癌良恶性鉴别诊断中的应用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background : Hepatic focal lesions include a heterogeneous group of lesions ranging from benign regenerative cirrhotic nodules to low and high grade dysplastic nodules to HCC. Hepatocellular carcinoma (HCC) is the most common type of all primary liver tumors. Liver cell dysplasia particularly high-grade dysplasia (HGD) has a high risk for malignant transformation. It is mandatory to find more accurate and comprehensive novel markers for diagnosis of HCC. Aim: To study the diagnostic role of clathrin heavy chain (CHC) and leukaemia inhibitory factor receptor (LIFR) in malignant and non-malignant liver lesions and correlation with the clinico-pathological parameters of studied cases. Results: CHC immunopositvity was highly specific and sensitive indicator for hepatocellular carcinoma unlike LIFR which cannot be used as reliable indicator of liver malignancy. Most of cases of HCC were positive for CHC (31 out of 33) (93.9%). Most of cases of cirrhosis (17 out of 25) (68.0%) were negative for CHC. In liver cell dysplasia, 14 cases were positive (70.0%) (P0.001). LIFR was more expressed in non-malignant than in HCC. 92% of cases of cirrhosis were positive for LIFR. 95% of cases of dyspalsia were positive for LIFR; only 30.3% of HCC showed positivity for LIFR. This inverse relation was statistically highly significant (p0.001). Conclusion : CHC can be a promising diagnostic immunomarker for the diagnosis of HCC unlike LIFR which can’t be a reliable diagnostic marker alone. However, a combination of both markers (CHC and LIFR) represents a valuable diagnostic tool in workout of hepatic lesions uncertain for malignancy rather than individual markers.
机译：背景：肝局灶性病变包括异类病变，范围从良性再生性肝硬化结节到低，高级别增生性结节到HCC。肝细胞癌（HCC）是所有原发性肝肿瘤中最常见的类型。肝细胞异型增生，特别是高度异型增生（HGD），具有高恶性转化风险。必须找到更准确和全面的新颖标志物来诊断HCC。目的：研究网格蛋白重链（CHC）和白血病抑制因子受体（LIFR）在恶性和非恶性肝病中的诊断作用及其与所研究病例的临床病理参数的关系。结果：与LIFR不同，CHC免疫阳性是肝细胞癌的高度特异性和灵敏指标，LIFR不能用作肝恶性肿瘤的可靠指标。大部分HCC病例的CHC阳性（33例中有31例）（93.9％）。大部分肝硬化病例（25例中有17例）（68.0％）的CHC阴性。在肝细胞异型增生中，有14例阳性（70.0％）（P <0.001）。 LIFR在非恶性肿瘤中的表达要高于HCC。 92％的肝硬化患者的LIFR阳性。 95％的发育不良患者的LIFR阳性;仅30.3％的HCC对LIFR呈阳性。这种反比关系在统计学上非常显着（p <0.001）。结论：与LIFR不同，CHC可以作为诊断HCC的有希望的诊断免疫标志物，而LIFR不能单独作为可靠的诊断标志物。但是，两种标记物（CHC和LIFR）的组合代表了在不确定恶性肿瘤而不是单个标记物的肝病灶锻炼中的有价值的诊断工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号